Effects of ACE inhibition on left ventricular dimensions and haemodynamics in systemic hypertension: a radionuclide

I C Haznedaroglu1, Y Erdem, L Tokgözoglu

  • 1Department of Cardiology, Hacettepe University, Medical Faculty, Ankara/Turkey.

The Central African Journal of Medicine
|April 1, 1995
PubMed

Insights

Enalapril, an Angiotensin Converting Enzyme (ACE) inhibitor, significantly lowers blood pressure and improves cardiac function in hypertensive patients. This treatment reduces left ventricular mass and enhances diastolic parameters, despite a slight decrease in cardiac output.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Essential hypertension poses significant cardiovascular risks.
  • Angiotensin Converting Enzyme (ACE) inhibitors are a cornerstone in managing hypertension.
  • Understanding the impact of ACE inhibition on cardiac structure and function is crucial.

Purpose of the Study:

  • To evaluate the effects of enalapril on cardiac systolic and diastolic parameters.
  • To assess the impact of enalapril on left ventricular muscle mass in hypertensive patients.
  • To determine changes in hemodynamic parameters following ACE inhibition.

Main Methods:

  • A prospective study involving 30 patients with mild to moderate essential hypertension.
  • Treatment with enalapril (an ACE inhibitor) for six weeks.
  • Assessment using M-mode and Doppler echocardiography and radionuclide ventriculography.

Main Results:

  • Significant reduction in mean arterial pressure (p < 0.001) and left ventricular mass index (p < 0.01).
  • Decreased total peripheral resistance and end-systolic stress (p < 0.001).
  • Improved time to peak filling rate (p < 0.02) and a non-significant increase in ejection fraction.

Conclusions:

  • Enalapril effectively improves diastolic and systolic parameters of left ventricular function in hypertensive patients.
  • ACE inhibition with enalapril leads to a reduction in blood pressure and left ventricular mass.
  • A slight decrease in cardiac output and stroke volume was observed alongside blood pressure reduction.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...